# Tier 5 Enumeration: Gastrointestinal Medications

> **Location in Hierarchy**:
> Tier 1: Medical > Tier 2: Medications > Tier 3: Prescription Medications > Tier 4: GI Medications > **Tier 5: Individual Cards**

---

## Overview

This document enumerates ALL individual Tier 5 cards for Gastrointestinal Medications. Each entry represents ONE SMART card with titratable doses handled within a single card.

**Total Estimated Cards**: ~50 cards

---

## Tier 4: Proton Pump Inhibitors (PPIs)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_PPI_001 | Omeprazole (Prilosec) | 20-40mg daily | GERD, PUD, H. pylori |
| MED_GI_PPI_002 | Esomeprazole (Nexium) | 20-40mg daily | GERD, PUD, H. pylori |
| MED_GI_PPI_003 | Pantoprazole (Protonix) | 40mg daily-BID | GERD, PUD, Zollinger-Ellison |
| MED_GI_PPI_004 | Lansoprazole (Prevacid) | 15-30mg daily | GERD, PUD, H. pylori |
| MED_GI_PPI_005 | Rabeprazole (Aciphex) | 20mg daily | GERD, PUD |
| MED_GI_PPI_006 | Dexlansoprazole (Dexilant) | 30-60mg daily | GERD |

**Subtotal: 6 cards**

---

## Tier 4: H2 Receptor Antagonists

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_H2_001 | Famotidine (Pepcid) | 20-40mg BID | GERD, PUD (preferred H2) |
| MED_GI_H2_002 | Cimetidine (Tagamet) | 200-800mg BID | GERD, PUD (many drug interactions) |
| MED_GI_H2_003 | Nizatidine (Axid) | 150-300mg BID | GERD, PUD |

**Subtotal: 3 cards**

---

## Tier 4: Antacids (Prescription Strength)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_ANTACID_001 | Sucralfate (Carafate) | 1g QID (before meals/HS) | PUD, mucosal protection |

**Subtotal: 1 card**

---

## Tier 4: Prokinetic Agents

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_PROKIN_001 | Metoclopramide (Reglan) | 5-10mg TID-QID (before meals) | Gastroparesis, GERD, N/V |
| MED_GI_PROKIN_002 | Erythromycin (Prokinetic dose) | 50-250mg TID | Gastroparesis (short-term) |

**Subtotal: 2 cards**

---

## Tier 4: Antiemetics - Serotonin (5-HT3) Antagonists

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_ANTI5HT_001 | Ondansetron (Zofran) | 4-8mg q8h PRN | N/V (chemo, post-op, general) |
| MED_GI_ANTI5HT_002 | Granisetron (Kytril) | 1-2mg daily | Chemo-induced N/V |
| MED_GI_ANTI5HT_003 | Palonosetron (Aloxi) | 0.25mg IV once | Chemo-induced N/V (long-acting) |

**Subtotal: 3 cards**

---

## Tier 4: Antiemetics - Other Mechanisms

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_ANTIEM_001 | Promethazine (Phenergan) | 12.5-25mg q4-6h | N/V, motion sickness |
| MED_GI_ANTIEM_002 | Prochlorperazine (Compazine) | 5-10mg TID-QID | N/V, vertigo |
| MED_GI_ANTIEM_003 | Scopolamine Patch (Transderm Scop) | 1 patch q3 days | Motion sickness, post-op N/V |
| MED_GI_ANTIEM_004 | Trimethobenzamide (Tigan) | 300mg TID-QID | N/V |
| MED_GI_ANTIEM_005 | Aprepitant (Emend) | 125mg day 1, 80mg days 2-3 | Chemo-induced N/V (NK1 antagonist) |
| MED_GI_ANTIEM_006 | Dronabinol (Marinol) | 2.5-10mg BID | Chemo-induced N/V, appetite |

**Subtotal: 6 cards**

---

## Tier 4: Laxatives - Osmotic

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_LAXOSM_001 | Polyethylene Glycol (MiraLAX) | 17g daily | Chronic constipation |
| MED_GI_LAXOSM_002 | Lactulose | 15-30mL daily-BID | Constipation, hepatic encephalopathy |
| MED_GI_LAXOSM_003 | Magnesium Citrate | 150-300mL once | Acute constipation, bowel prep |
| MED_GI_LAXOSM_004 | Sorbitol | 30-60mL daily | Constipation |

**Subtotal: 4 cards**

---

## Tier 4: Laxatives - Stimulant

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_LAXSTIM_001 | Bisacodyl (Dulcolax) | 5-15mg daily | Acute/chronic constipation |
| MED_GI_LAXSTIM_002 | Senna (Senokot) | 8.6-17.2mg daily-BID | Opioid-induced constipation |

**Subtotal: 2 cards**

---

## Tier 4: Laxatives - Other Mechanisms

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_LAXOTH_001 | Docusate (Colace) | 100-300mg daily | Stool softener |
| MED_GI_LAXOTH_002 | Lubiprostone (Amitiza) | 8-24mcg BID | CIC, IBS-C, OIC |
| MED_GI_LAXOTH_003 | Linaclotide (Linzess) | 72-290mcg daily | CIC, IBS-C |
| MED_GI_LAXOTH_004 | Plecanatide (Trulance) | 3mg daily | CIC, IBS-C |
| MED_GI_LAXOTH_005 | Prucalopride (Motegrity) | 1-2mg daily | Chronic constipation (prokinetic) |
| MED_GI_LAXOTH_006 | Naloxegol (Movantik) | 12.5-25mg daily | Opioid-induced constipation |
| MED_GI_LAXOTH_007 | Methylnaltrexone (Relistor) | 8-12mg SQ q other day | OIC (peripheral antagonist) |

**Subtotal: 7 cards**

---

## Tier 4: Antidiarrheals

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_ANTIDIAR_001 | Loperamide (Imodium) | 2-4mg PRN (max 16mg/day) | Acute/chronic diarrhea |
| MED_GI_ANTIDIAR_002 | Diphenoxylate/Atropine (Lomotil) | 5mg QID PRN | Diarrhea |
| MED_GI_ANTIDIAR_003 | Eluxadoline (Viberzi) | 75-100mg BID | IBS-D |
| MED_GI_ANTIDIAR_004 | Rifaximin (Xifaxan) | 550mg TID x 14 days | IBS-D, hepatic encephalopathy |
| MED_GI_ANTIDIAR_005 | Alosetron (Lotronex) | 0.5-1mg BID | Severe IBS-D (women, restricted) |

**Subtotal: 5 cards**

---

## Tier 4: Antispasmodics

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_SPASM_001 | Dicyclomine (Bentyl) | 10-20mg QID | IBS, GI spasm |
| MED_GI_SPASM_002 | Hyoscyamine (Levsin) | 0.125-0.25mg QID PRN | IBS, GI spasm |

**Subtotal: 2 cards**

---

## Tier 4: IBD Medications - 5-ASA Agents

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_5ASA_001 | Mesalamine (Asacol HD, Lialda, Pentasa) | 2.4-4.8g daily | Ulcerative colitis |
| MED_GI_5ASA_002 | Mesalamine Enema (Rowasa) | 4g HS | Left-sided UC |
| MED_GI_5ASA_003 | Mesalamine Suppository (Canasa) | 1g daily | UC proctitis |
| MED_GI_5ASA_004 | Sulfasalazine (Azulfidine) | 3-6g daily (divided) | UC, Crohn's |
| MED_GI_5ASA_005 | Balsalazide (Colazal) | 2.25g TID | UC |
| MED_GI_5ASA_006 | Olsalazine (Dipentum) | 500mg BID | UC |

**Subtotal: 6 cards**

---

## Tier 4: IBD Medications - Immunomodulators

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_IMM_001 | Azathioprine (Imuran) | 2-2.5mg/kg daily | IBD maintenance |
| MED_GI_IMM_002 | 6-Mercaptopurine (Purinethol) | 1-1.5mg/kg daily | IBD maintenance |
| MED_GI_IMM_003 | Methotrexate | 15-25mg weekly | Crohn's disease |

**Subtotal: 3 cards**

---

## Tier 4: IBD Medications - Biologics

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_BIO_001 | Infliximab (Remicade) | 5mg/kg IV at 0,2,6 wks then q8wks | Crohn's, UC (anti-TNF) |
| MED_GI_BIO_002 | Adalimumab (Humira) | 160mg, then 80mg, then 40mg q2wks | Crohn's, UC (anti-TNF) |
| MED_GI_BIO_003 | Certolizumab (Cimzia) | 400mg at 0,2,4 wks then q4wks | Crohn's (anti-TNF) |
| MED_GI_BIO_004 | Golimumab (Simponi) | 200mg, then 100mg, then 100mg q4wks | UC (anti-TNF) |
| MED_GI_BIO_005 | Vedolizumab (Entyvio) | 300mg IV at 0,2,6 wks then q8wks | Crohn's, UC (gut-selective) |
| MED_GI_BIO_006 | Ustekinumab (Stelara) | 260-520mg IV once, then 90mg SQ q8wks | Crohn's, UC (IL-12/23) |
| MED_GI_BIO_007 | Risankizumab (Skyrizi) | 600mg IV at 0,4,8 wks, then 180-360mg SQ q8wks | Crohn's (IL-23) |

**Subtotal: 7 cards**

---

## Tier 4: Hepatic Encephalopathy

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_GI_HE_001 | Lactulose (for HE) | 30-45mL TID-QID | Hepatic encephalopathy |
| MED_GI_HE_002 | Rifaximin (for HE) | 550mg BID | HE prevention |

**Subtotal: 2 cards**

---

## Summary

| Tier 4 Category | Card Count |
|-----------------|------------|
| Proton Pump Inhibitors (PPIs) | 6 |
| H2 Receptor Antagonists | 3 |
| Antacids (Prescription) | 1 |
| Prokinetic Agents | 2 |
| Antiemetics - 5-HT3 Antagonists | 3 |
| Antiemetics - Other | 6 |
| Laxatives - Osmotic | 4 |
| Laxatives - Stimulant | 2 |
| Laxatives - Other | 7 |
| Antidiarrheals | 5 |
| Antispasmodics | 2 |
| IBD - 5-ASA Agents | 6 |
| IBD - Immunomodulators | 3 |
| IBD - Biologics | 7 |
| Hepatic Encephalopathy | 2 |
| **TOTAL** | **59 cards** |

---

## Card Naming Convention

**Format**: `MED_GI_[SUBCLASS]_[NUMBER]`

**Subclass Abbreviations**:
- `PPI` = Proton Pump Inhibitors
- `H2` = H2 Receptor Antagonists
- `ANTACID` = Antacids
- `PROKIN` = Prokinetics
- `ANTI5HT` = 5-HT3 Antagonists
- `ANTIEM` = Other Antiemetics
- `LAXOSM` = Osmotic Laxatives
- `LAXSTIM` = Stimulant Laxatives
- `LAXOTH` = Other Laxatives
- `ANTIDIAR` = Antidiarrheals
- `SPASM` = Antispasmodics
- `5ASA` = 5-Aminosalicylic Acid Agents
- `IMM` = Immunomodulators
- `BIO` = Biologics
- `HE` = Hepatic Encephalopathy

---

## Notes

1. **Titratable doses within single card**: Each card covers full dose range
2. **OTC equivalents**: Many PPIs, H2s, and laxatives have OTC versions - those are listed under OTC/Supplements Tier 3
3. **Lactulose appears twice**: Listed in both laxatives and HE categories with different dosing/indications - use tags for cross-reference
4. **IBD biologics**: These have significant overlap with rheumatology/dermatology uses - primary location here for GI indications
5. **Not included**: H. pylori treatment regimens (multi-drug) - will be a separate protocol card

---

## Clinical Pearls for Card Development

When developing individual cards, ensure:

1. **PPI Cards**: Include long-term risks (bone fracture, C. diff, B12 deficiency, kidney), deprescribing guidance
2. **Metoclopramide Cards**: Black box warning for tardive dyskinesia, max 12 weeks use
3. **Ondansetron Cards**: QT prolongation risk, constipation side effect
4. **Laxative Cards**: Include bowel regimen guidance for opioid patients
5. **IBD Biologic Cards**: TB screening, infection monitoring, injection training, biosimilar options
6. **5-ASA Cards**: Include kidney monitoring, sulfa allergy considerations for sulfasalazine

---

*Version 1.0 | Created: 2024-11-23*
*Source: LIBRARY_TIER_STRUCTURE.md*
